WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.


G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

This group comprises drugs modifying the genital functions, which cannot be classified in the preceding groups.
Tibolone is classified in G03DC.


G03XA Antigonadotropins and similar agents

The DDDs of danazol and gestrinone are based on the treatment of endometriosis.

G03XB Progesterone receptor modulators

Mifepristone indicated for Cushingss syndrome is also classified in this group.
The combination package of mifepristone tablet and misoprostol vaginal tablets is classified in G03XB51.

The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.
The DDD for the combination package is given as amount of mifepristone.

G03XC Selective estrogen receptor modulators
G03XX Other sex hormones and modulators of the genital system

Vaginal formulations of prasterone are classified here while systemic formulations (tablets/injections) are classified in A14AA.

Last updated: 2024-01-26